Successful debulking of plurihormonal pituitary macroadenoma with long-acting pasireotide and dopamine agonist combination therapy

Terri W Jerkins; Randy K Jerkins; Robbi Franklin

doi:10.1002/ccr3.1961

Successful debulking of plurihormonal pituitary macroadenoma with long-acting pasireotide and dopamine agonist combination therapy

Clin Case Rep. 2019 Jan 28;7(3):445-451. doi: 10.1002/ccr3.1961. eCollection 2019 Mar.

Authors

Terri W Jerkins^{1

2}, Randy K Jerkins², Robbi Franklin³

Affiliations

¹ Midstate Endocrinology Associates Nashville Tennessee.
² College of Pharmacy Lipscomb University Nashville Tennessee.
³ Nashville Neurosurgery Group Nashville Tennessee.

Abstract

Long-acting pasireotide and bromocriptine provided biochemical control of growth hormone and prolactin in a patient with plurihormonal pituitary macroadenoma, allowing near-complete tumor excision while restoring pituitary function and avoiding adjunctive radiotherapy. Pasireotide initiation resulted in hyperglycemia, which stabilized after a few months and resolved upon pasireotide discontinuation (ACCESS; NCT01995734).

Keywords: endocrinology; metabolic disorders; pasireotide and bromocriptine.

Publication types

Case Reports

Associated data

ClinicalTrials.gov/NCT01995734